Inhibition of Carbonic Anhydrase IX Suppresses Breast Cancer Cell Motility at the Single-Cell Level.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Oct 2021
Historique:
received: 26 09 2021
revised: 21 10 2021
accepted: 24 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 16 12 2021
Statut: epublish

Résumé

Protein Carbonic Anhydrase IX (CA IX), which is expressed in various hypoxic solid tumors in order to maintain proper pH, is also related to cancer cell adhesion, invasion, and metastasis processes. Here, we investigated whether CA IX inhibition by a highly CA IX selective agent benzenesulfonamide VD11-4-2 triggers changes in individual cell motility. We seeded breast cancer cells on an extracellular matrix-coated glass-bottomed dish and in a microfluidic device with a gradient flow of epidermal growth factor (EGF), tracked individual cell movement, calculated their migration speeds, and/or followed movement direction. Our results showed that the inhibitor VD11-4-2 decreased the speed of CA IX positive breast cancer cells by 20-26% while not affecting non-cancerous cell migration. The inhibitor suppressed the cell migration velocity increment and hindered cells from reaching their maximum speed. VD11-4-2 also reduced CA IX, expressing cell movement towards the growth factor as a chemoattractant. Such a single cell-based migration assay enabled the comprehensive investigation of the cell motility and revealed that VD11-4-2 shows the ability to suppress breast cancer cell migration at a lower concentration than previously tested CA IX inhibitors.

Identifiants

pubmed: 34769000
pii: ijms222111571
doi: 10.3390/ijms222111571
pmc: PMC8584155
pii:
doi:

Substances chimiques

Carbonic Anhydrase Inhibitors 0
Sulfonamides 0
Carbonic Anhydrase IX EC 4.2.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Oncogene. 2014 Jan 30;33(5):550-5
pubmed: 23396364
J Med Chem. 2012 Jun 14;55(11):5591-600
pubmed: 22621623
Nat Med. 2013 Nov;19(11):1450-64
pubmed: 24202397
Int J Mol Sci. 2019 Jun 04;20(11):
pubmed: 31167468
Semin Cell Dev Biol. 2009 Oct;20(8):931-41
pubmed: 19682592
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
Biophys J. 2018 Nov 20;115(10):2034-2043
pubmed: 30366624
J Enzyme Inhib Med Chem. 2016;31(sup4):38-44
pubmed: 27557419
BMC Dev Biol. 2009 Mar 16;9:22
pubmed: 19291313
Adv Drug Deliv Rev. 2016 Feb 1;97:41-55
pubmed: 26743193
Adv Healthc Mater. 2017 Jun;6(11):
pubmed: 28272780
Breast Cancer Res. 2011 Jul 11;13(4):R71
pubmed: 21745383
Dev Cell. 2019 May 6;49(3):332-346
pubmed: 31063753
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340282
Exp Cell Res. 2004 Oct 15;300(1):180-9
pubmed: 15383325
Exp Cell Res. 2003 Nov 1;290(2):332-45
pubmed: 14567991
J Med Chem. 2014 Nov 26;57(22):9435-46
pubmed: 25358084
Int J Oncol. 2016 Jan;48(1):271-80
pubmed: 26648580
Molecules. 2015 Jan 30;20(2):2323-48
pubmed: 25647573
Br J Cancer. 2007 Jan 15;96(1):104-9
pubmed: 17213826
Nat Rev Clin Oncol. 2019 Mar;16(3):185-204
pubmed: 30514977
Oncol Rep. 2019 Apr;41(4):2585-2594
pubmed: 30720123
Anticancer Res. 2015 Jun;35(6):3147-54
pubmed: 26026074
Cancer Med. 2019 Sep;8(12):5574-5576
pubmed: 31397113
ACS Appl Mater Interfaces. 2017 Apr 26;9(16):13976-13987
pubmed: 28383881
Cold Spring Harb Perspect Biol. 2018 Jan 2;10(1):
pubmed: 29295889
BMC Cancer. 2014 Nov 22;14:864
pubmed: 25417118
PLoS One. 2018 Sep 13;13(9):e0203040
pubmed: 30212492
Med Res Rev. 2007 Mar;27(2):149-76
pubmed: 16888756
Oncotarget. 2015 Sep 22;6(28):24856-70
pubmed: 26259239
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Biomolecules. 2019 Jul 25;9(8):
pubmed: 31349673
Cell Adh Migr. 2013 Mar-Apr;7(2):226-31
pubmed: 23302955
Cell Commun Signal. 2014 Oct 05;12:54
pubmed: 25288205
Oncogene. 2017 Nov 9;36(45):6244-6261
pubmed: 28692057
Oncotarget. 2018 Jun 1;9(42):26800-26816
pubmed: 29928486
Drug Chem Toxicol. 2017 Jul;40(3):309-319
pubmed: 27600313
Front Physiol. 2013 Oct 01;4:271
pubmed: 24101905
Oncogene. 2013 Oct 31;32(44):5210-9
pubmed: 23208505
Oncotarget. 2016 Dec 20;7(51):85021-85032
pubmed: 27829223

Auteurs

Agne Janoniene (A)

Institute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.

Linas Mazutis (L)

Institute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.

Daumantas Matulis (D)

Institute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.

Vilma Petrikaite (V)

Institute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH